|
|
||||||||





* Ludwig Institute for Cancer Research, Brussels Branch and Cellular Genetics Unit, Université de Louvain, Brussels, Belgium;
Third Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany;
Laboratory of Molecular and Cellular Therapy, Medical School of the Vrije Universiteit Brussel, Brussels, Belgium; and
Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Quantitative evaluation of T cell responses of patients receiving antitumoral vaccination with a protein is difficult because of the large number of possible HLA-peptide combinations that could be targeted by the response. To evaluate the responses of patients vaccinated with protein MAGE-3, we have developed an approach that involves overnight stimulation of blood T cells with autologous dendritic cells loaded with the protein, sorting by flow cytometry of the T cells that produce IFN-
, cloning of these cells, and evaluation of the number of T cell clones that secrete IFN-
upon stimulation with the Ag. An important criterion is that T cell clones must recognize not only stimulator cells loaded with the protein, but also stimulator cells transduced with the MAGE-3 gene, so as to exclude the T cells that recognize contaminants generated by the protein production system. Using this approach it is possible to measure T cell frequencies as low as 106. We analyzed the frequencies of anti-vaccine CD4 T cells in five metastatic melanoma patients who had been injected with a MAGE-3 protein without adjuvant and showed evidence of tumor regression. Anti-MAGE-3 CD4 T cells were detected in one of the five patients. The frequency of the anti-MAGE-3 CD4 T cells was estimated at 1/60,000 of the CD4 T cells in postvaccination blood samples, representing at least an 80-fold increase in the frequency found before immunization. The frequencies of one anti-MAGE-3 CD4 T cell clonotype were confirmed by PCR analysis on blood lymphocytes. The 13 anti-MAGE-3 clones, which corresponded to five different TCR clonotypes, recognized the same peptide presented by HLA-DR1.
This article has been cited by other articles:
![]() |
G. Bioley, P. Guillaume, I. Luescher, A. Yeh, B. Dupont, N. Bhardwaj, G. Mears, L. J. Old, D. Valmori, and M. Ayyoub HLA Class I-Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine Clin. Cancer Res., January 1, 2009; 15(1): 299 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Atanackovic, N. K. Altorki, Y. Cao, E. Ritter, C. A. Ferrara, G. Ritter, E. W. Hoffman, C. Bokemeyer, L. J. Old, and S. Gnjatic Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming PNAS, February 5, 2008; 105(5): 1650 - 1655. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |